The TREM2-SYK signaling cascade represents a critical neuroimmune pathway in Alzheimer's disease (AD) and related neurodegenerative disorders. TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial surface receptor that recognizes lipid antigens, amyloid-beta plaques, and cellular debris, triggering intracellular signaling through SYK (Spleen Tyrosine Kinase) to coordinate the microglial response to pathology.
This pathway sits at the intersection of innate immunity and neurodegeneration, regulating microglial phagocytosis, inflammatory responses, cell survival, and the clearance of toxic protein aggregates. Rare TREM2 variants dramatically increase AD risk, highlighting the essential role of this pathway in brain immune surveillance.
¶ Structure and Expression
TREM2 is a single-pass transmembrane receptor belonging to the immunoglobulin superfamily:
Extracellular domain: The V-type immunoglobulin-like domain contains the ligand-binding site, recognizing lipids, apolipoproteins, and amyloid-beta aggregates.
Transmembrane domain: A short hydrophobic helix anchors TREM2 in the microglial membrane, with a charged lysine residue for interaction with the adaptor protein DAP12.
Cytoplasmic domain: TREM2 lacks a cytoplasmic signaling domain and signals through association with the adaptor protein DAP12 (also known as TYROBP).
TREM2 is expressed primarily on:
- Microglia: The dominant TREM2-expressing cell in the brain
- Macrophages: Peripheral immune cells
- Osteoclasts: Bone-resorbing cells
- Dendritic cells: Antigen-presenting cells
In the brain, TREM2 expression increases in response to AD pathology, with disease-associated microglia (DAM) showing the highest expression levels.
DAP12 (DNAX-activating protein 12) is a transmembrane adaptor protein containing an immunoreceptor tyrosine-based activation motif (ITAM):
Structure:
- ITAM motif: YxxL/I sequence (Y = tyrosine)
- Associates with TREM2 via charged transmembrane residues
- Recruits SYK family kinases upon activation
- Ligand binding: TREM2 recognizes lipids, Aβ, or cellular debris
- Receptor clustering: Ligand binding induces TREM2 clustering
- ITAM phosphorylation: DAP12 ITAM tyrosines are phosphorylated by SRC family kinases
- SYK recruitment: SYK binds phosphorylated ITAM via its SH2 domains
- Signal propagation: SYK activates downstream signaling cascades
¶ SYK Kinase and Downstream Pathways
¶ SYK Structure and Activation
Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase essential for TREM2 signaling:
Domains:
- Two N-terminal SH2 domains: Bind phosphorylated ITAM
- C-terminal kinase domain: Catalytic activity
- Linker regions: Regulatory function
Activation mechanism:
- Binding to doubly-phosphorylated ITAM
- Autophosphorylation of activation loop tyrosines
- Conformational change to active state
flowchart TD
subgraph TREM2_Activation
TREM2["TREM2"] -->|"binds"| Ligand["Lipids<br/>Aβ<br/>Debris"]
Ligand -->|"clusters"| TREM2_Cluster["TREM2<br/>Cluster"]
TREM2_Cluster -->|" recruits"| DAP12["DAP12<br/>ITAM"]
DAP12 -->|"phosphorylates"| pDAP12["Phospho<br/>DAP12"]
pDAP12 -->|"recruits"| SYK["SYK"]
end
subgraph Signaling_Branches
SYK -->|"activates"| PLCG["PLCγ"]
SYK -->|"activates"| PI3K["PI3K"]
SYK -->|"activates"| MAPK["MAPK"]
SYK -->|"activates"| CARD9["CARD9"]
PLCG -->|"generates"| DAG["DAG/IP3"]
DAG -->|"activates"| PKC["PKC"]
PI3K -->|"generates"| PIP3["PIP3"]
PIP3 -->|"activates"| AKT["AKT/mTOR"]
MAPK -->|"activates"| ERK["ERK1/2"]
CARD9 -->|"activates"| NFKB["NF-κB"]
end
subgraph Cellular_Responses
PKC -->|"regulates"| Phagocytosis["Phagocytosis"]
AKT -->|"regulates"| Survival["Cell Survival"]
ERK -->|"regulates"| Cytokines["Cytokine<br/>Production"]
NFKB -->|"regulates"| Genes["Inflammatory<br/>Genes"]
end
Phagocytosis -->|"clearance"| Ab["Aβ<br/>Plaques"]
Survival -->|"protection"| Neurons["Neurons"]
style TREM2 fill:#b3e5fc,stroke:#333
style SYK fill:#c8e6c9,stroke:#333
style Phagocytosis fill:#ff9,stroke:#333
style Survival fill:#9f9,stroke:#333
Phospholipase C gamma (PLCγ):
- Generates DAG and IP3
- Activates PKC isoforms
- Increases intracellular calcium
- Regulates cytoskeletal dynamics for phagocytosis
Phosphatidylinositol 3-kinase (PI3K):
- Generates PIP3
- Activates AKT/mTOR pathway
- Promotes cell survival
- Regulates autophagy
MAPK pathway:
- Activates ERK1/2
- Controls inflammatory gene expression
- Regulates cell proliferation
CARD9 complex:
- Activates NF-κB pathway
- Drives pro-inflammatory cytokine production
- Links to inflammasome activation
The TREM2-SYK cascade is essential for microglial phagocytosis of:
Target substrates:
- Amyloid-beta plaques and oligomers
- Apoptotic neurons and debris
- Lipid droplets and cellular remnants
- Synaptic material (synaptic pruning)
Phagocytic machinery:
- Actin cytoskeleton remodeling
- Phagosome formation
- Lysosomal fusion
- Antigen processing and presentation
TREM2 signaling modulates neuroinflammation:
Pro-inflammatory:
- IL-1β, IL-6, TNF-α production
- Nitric oxide generation
- Matrix metalloproteinase expression
Anti-inflammatory:
- IL-10 production
- TGF-β secretion
- Arginase-1 expression (alternative activation)
The balance depends on ligand context and disease stage.
TREM2 supports microglial survival and metabolic fitness:
- mTOR activation: Promotes protein synthesis and metabolic adaptation
- Autophagy: Enhances clearance of intracellular aggregates
- Lipid metabolism: Facilitates lipid processing and foam cell formation
- Energy production: Supports oxidative phosphorylation
SYK activation regulates:
- Actin polymerization
- Membrane ruffling
- Phagocytic cup formation
- Cell migration
¶ TREM2 Variants and Alzheimer's Disease Risk
Rare TREM2 variants significantly alter AD risk:
| Variant |
AD Risk |
Effect |
Population Frequency |
| R47H |
~3x increased |
Loss of function |
~0.3% European |
| R62H |
~2x increased |
Partial loss |
~0.5% European |
| T66M |
Increased |
Misfolding |
Rare |
| Y38C |
Increased |
Misfolding |
Rare |
| D87N |
Increased |
Partial loss |
Rare |
Risk variants impair TREM2 function:
- Lipid binding: Reduced ligand recognition
- Signaling: Decreased SYK activation
- Phagocytosis: Impaired clearance of Aβ
- Microglial response: Attenuated disease-associated phenotype
¶ TREM2 and Risk for Other Diseases
TREM2 variants are associated with:
- Frontotemporal dementia: Some variants
- ALS: Protective variants identified
- Nasu-Hakola disease: Biallelic loss-of-function
| Approach |
Compound |
Stage |
Mechanism |
| Agonist antibody |
AL002c |
Phase I/II |
TREM2 activation |
| Agonist antibody |
HL-002 |
Preclinical |
TREM2 activation |
| Small molecule |
Unknown |
Discovery |
TREM2 activation |
| Gene therapy |
AAV-TREM2 |
Preclinical |
Increase TREM2 expression |
SYK is also a therapeutic target:
| Compound |
Stage |
Notes |
| Fostamatinib |
FDA-approved (ITP) |
Oral SYK inhibitor |
| R406 |
Preclinical |
Selective SYK inhibitor |
| PRT318 |
Phase I |
Brain-penetrant |
Rational combinations for AD:
- TREM2 agonist + anti-Aβ antibody: Enhanced plaque clearance
- TREM2 agonist + anti-inflammatory: Balanced immune modulation
- SYK inhibitor + tau targeting: Reduce propagation
TREM2 drives the transition from homeostatic to disease-associated microglia (DAM):
Stage 1 DAM:
- TREM2-independent
- Upregulation of Apoe, Ctsd
Stage 2 DAM:
- TREM2-dependent
- Upregulation of TREM2, Tyrobp, Cd68
- Phagocytic activation
- Lipid metabolism genes
¶ TREM2 and Amyloid Pathology
The TREM2-SYK axis modulates amyloid clearance:
- Efficient clearance: Normal TREM2 function removes Aβ
- Impaired clearance: Risk variants allow plaque accumulation
- Plaque association: TREM2+ microglia cluster around plaques
¶ TREM2 and Tau Pathology
TREM2 also affects tau pathogenesis:
- Tau spreading: TREM2 deficiency may enhance propagation
- Neuronal loss: TREM2 loss accelerates tau-induced degeneration
- Inflammation: TREM2 regulates tau-induced inflammation
The TREM2-SYK cascade connects to multiple neurodegenerative mechanisms:
The TREM2-SYK signaling cascade is a master regulator of microglial immune function in the brain. Through recognition of lipid antigens, amyloid-beta, and cellular debris, TREM2 initiates intracellular signaling via the DAP12 adaptor protein to SYK kinase, activating downstream pathways that control phagocytosis, inflammatory responses, and cell survival.
The discovery that rare TREM2 variants dramatically increase AD risk underscores the essential role of this pathway in brain immune surveillance and neuroprotection. Therapeutic strategies targeting TREM2 activation or SYK inhibition offer promising approaches for enhancing microglial clearance of pathological aggregates while modulating neuroinflammation.
Future research should focus on:
- Agonist development: Brain-penetrant TREM2 activators
- Biomarkers: Circulating TREM2 as disease marker
- Timing: Optimal intervention in disease progression
- Combination: TREM2-targeted with other modalities
¶ TREM2 Ligand Recognition
¶ Identified Ligands
TREM2 recognizes a diverse array of ligands:
Lipid ligands:
- Apolipoproteins: APOE, APOA1, APOJ
- Phospholipids: Phosphatidylserine, phosphatidylcholine
- Lipid A derivatives: Bacterial lipid recognition
Protein ligands:
Nucleic acid ligands:
- Bacterial DNA: TLR-independent recognition
- Viral RNA: Emerging evidence
¶ Ligand Binding Mechanisms
The TREM2 extracellular domain recognizes:
- Lipid rafts: Membrane microdomains as ligand platforms
- ApoE-containing complexes: Lipidated APOE from astrocytes
- Phosphatidylserine: "Eat-me" signal on apoptotic cells
- Aβ aggregates: Oligomeric and fibrillar forms
¶ Structural Basis of Ligand Recognition
Cryo-EM and crystallography studies reveal:
- Hydrophobic pocket: Binds lipid moieties
- Complementary surface: Recognizes protein aggregates
- Conformational flexibility: Adapts to diverse ligands
¶ DAP12 Structure and Function
DAP12 (DNAX-activating protein of 12 kDa) is a critical signaling adaptor:
Amino acid structure:
- ITAM motif: YxxL/I (Y = tyrosine)
- Dimerization interface
- Transmembrane connector
Expression:
- Broad myeloid cell expression
- Essential for TREM2 function
- Also signals other receptors
- SRC activation: SRC family kinases phosphorylate ITAM tyrosines
- SYK recruitment: Dual SH2 domains bind phosphorylated ITAM
- Activation loop phosphorylation: SYK autophosphorylates
- Substrate phosphorylation: SYK phosphorylates downstream targets
- Signal amplification: Multiple DAP12 molecules per TREM2 cluster
SYK activation involves multiple mechanisms:
ITAM binding:
- Both SH2 domains required
- Cooperative binding increases affinity
- Membrane proximity facilitates activation
Autophosphorylation:
- Activation loop tyrosines (Y352, Y525, Y526)
- Interdomain autophosphorylation
- Kinase activity enhancement
Conformational changes:
- Open conformation upon activation
- Linker region becomes accessible
- Catalytic site activation
SYK is regulated by:
- Phosphatases: Dephosphorylation terminates signaling
- Inhibitory phosphorylation: Negative regulatory sites
- Adaptor proteins: Additional regulation layers
TREM2-SYK controls phagocytosis through:
** actin Dynamics:**
- VAV family GEFs: Rac, Rho activation
- WASP/WAVE: Arp2/3 complex activation
- Formins: Filament elongation
Membrane remodeling:
- PI(4,5)P2 generation: Phagosome formation
- BAR domain proteins: Membrane curvature
- SNARE complexes: Membrane fusion
Phagosome maturation:
- Early endosome markers
- Late endosome/lysosome fusion
- Acidification and degradation
SYK activation drives transcription:
Transcription factors:
- NF-κB: Pro-inflammatory genes
- AP-1: Cell survival and proliferation
- NFAT: Calcium-dependent genes
Cytokine production:
- TNF-α: Pro-inflammatory cytokine
- IL-1β: Pyrogenic and inflammatory
- IL-6: Acute phase response
- IL-10: Anti-inflammatory feedback
TREM2 signaling supports metabolism:
mTOR pathway:
- Protein synthesis
- Lipid biosynthesis
- Autophagy regulation
Glycolysis:
- Increased glucose uptake
- Lactate production
- Metabolic switching
Oxidative phosphorylation:
- Mitochondrial function
- ATP production
- ROS management
TREM2 supports baseline microglial function:
- Process motility: Constant brain surveillance
- Debris clearance: Continuous cleaning
- Synaptic maintenance: Activity-dependent pruning
- Metabolic support: Neuronal energy needs
¶ Development and Plasticity
During brain development:
- Synaptic pruning: Remove inappropriate synapses
- Neuronal survival: Trophic factor support
- Circuit refinement: Activity-dependent elimination
¶ Aging and Adaptation
With age, TREM2 function changes:
- Compensatory upregulation: Increased expression with age
- Epigenetic changes: Methylation patterns
- Functional decline: Reduced signaling capacity
¶ TREM2 and Disease Progression
In prodromal AD:
- DAM induction: TREM2 drives microglial response
- Aβ clearance: Attempted plaque removal
- Neuroprotection: Support of neuronal health
During progression:
- Chronic activation: Sustained signaling
- Dysfunctional state: Impaired clearance
- Inflammation: Contributing to pathology
Advanced disease:
- Exhaustion: Microglial failure
- Propagating pathology: Inadequate protection
- Neurodegeneration: Progressive loss
TREM2 research utilizes multiple models:
Knockout mice:
- TREM2-/-: Complete loss of function
- DAP12-/-: Downstream signaling loss
- Conditional knockouts: Cell-type specific
Knock-in mice:
- R47H knock-in: Human risk variant
- Reporter mice: TREM2 expression tracking
Transgenic models:
- Overexpression: Human TREM2
- Disease models: 5xFAD, APP/PS1
Cell culture models include:
- Primary microglia: Murine and human
- iPSC-derived microglia: Patient-specific
- Cell lines: BV2, RAW264.7
TREM2 as a biomarker:
- Soluble TREM2: sTREM2 in CSF and plasma
- Expression levels: Disease stage correlation
- Genetic stratification: Variant carriers
TREM2 status informs treatment:
- Variant carriers: May respond differently
- Disease stage: Timing of intervention
- Microglial state: Target engagement
Treatment response indicators:
- sTREM2 levels: Target engagement
- Microglial imaging: PET ligands
- Functional assessments: Cognitive measures
- Ligand identification: Complete ligand repertoire?
- Signaling specificity: How is pathway specificity achieved?
- Therapeutic timing: When is intervention most effective?
- Combination therapy: Optimal partners?
- Single-cell analysis: TREM2 heterogeneity
- Spatial transcriptomics: Regional effects
- Human models: iPSC and organoids